Sinopharm : ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF CNMDC FOR THE THREE MONTHS ENDED 31 MARCH 2021
April 26, 2021 at 07:17 am EDT
Share
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)
ANNOUNCEMENT
PRINCIPAL FINANCIAL DATA OF CNMDC
FOR THE THREE MONTHS ENDED 31 MARCH 2021
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).
Reference is made to the overseas regulatory announcement dated 26 April 2021 (the "Announcement") issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the unaudited consolidated balance sheet, income statement and cash flow statement, and the unaudited balance sheet, income statement and cash flow statement of China National Medical Device Co., Ltd. (中國醫療器械有限公司)("CNMDC"), a subsidiary of the Company for the three months ended 31 March 2021 (the "Reporting Period") issued by CNMDC on the websites of China Money and Shanghai Clearing House.
The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the three months ended 31 March 2021 as set out in the Announcement.
1
PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS
Unit: Yuan
Currency: RMB
Changes of this The Reporting Period Same period of last year period over the same period of last year
Revenue Operating profit
Total comprehensive income attributable to owners of the parent company
Net cash flow arising from operating activities
Total assets
Total equity attributable to owners of the parent company
14,111,844,359.67
501,446,953.21
213,890,050.95
-4,696,462,346.88
At the end of the Reporting Period
39,832,920,930.22
5,561,172,130.24
9,239,323,674.16
52.74%
345,879,603.08
44.98%
130,532,220.39
63.86%
-3,654,837,058.60
28.50%
Changes of this
At the beginning of the
period-end over the
Reporting Period
beginning of this
period
38,228,498,838.96
4.20%
5,347,282,079.29
4.00%
By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman
Shanghai, the PRC
26 April 2021
As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.
The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".
2
Attachments
Original document
Permalink
Disclaimer
Sinopharm Group Co. Ltd. published this content on 26 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 April 2021 11:16:04 UTC.
Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.